Dietary administration of δ- and γ-tocopherol inhibits tumorigenesis in the animal model of estrogen receptor-positive, but not HER-2 breast cancer

Cancer Prevention Research

Volumn 5, Issue 11, 2012, Pages 1310-1320

  Smolarek, Amanda K ^a,b   So, Jae Young ^b   Burgess, Brenda ^b   Kong, Ah Ng Tony ^a,d   Reuhl, Kenneth ^a,d   Lin, Yong ^c,d   Shih, Weichung Joe ^c,d   Li, Guangxun ^b   Lee, Mao Jung ^b   Chen, Yu Kuo ^b   Yang, Chung S ^b,d   Suh, Nanjoo ^b,d  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CASPASE 3; CASPASE 9; CYCLINE; DELTA TOCOPHEROL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GAMMA TOCOPHEROL; GAMMA TOCOPHEROL RICH MIXTURE; METHYLNITROSOUREA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RAT; TUMOR VOLUME;

ANIMALS; BREAST NEOPLASMS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; GAMMA-TOCOPHEROL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TOCOPHEROLS;

EID: 84870225095     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0263     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Khan N, Afaq F, Mukhtar H. Lifestyle as risk factor for cancer: evidence from human studies. Cancer Lett 2010;293:133-43.
3. International Agency for Cancer Research: World Cancer Report 2008. Lyon, France: IARC; 2008.
4. Tan AC, Konczak I, Sze DM, Ramzan I. Molecular pathways for cancer chemoprevention by dietary phytochemicals. Nutr Cancer 2011;63:495-505.
5. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768-80.
6. Constantinou C, Papas A, Constantinou AI. Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int J Cancer 2008;123:739-52. (Pubitemid 352032398)
7. Burton GW, Ingold KU. Vitamin E as an in vitro and in vivo antioxidant. Ann N Y Acad Sci 1989;570:7-22. (Pubitemid 20103380)
8. Kamal-Eldin A, Appelqvist LA. The chemistry and antioxidant properties of tocopherols and tocotrienols. Lipids 1996;31:671-701. (Pubitemid 26240763)
9. Cooney RV, Franke AA, Harwood PJ, Hatch-Pigott V, Custer LJ, Mordan LJ. Gamma-tocopherol detoxification of nitrogen dioxide: superiority to alpha-tocopherol. Proc Natl Acad Sci U S A 1993;90:1771-5. (Pubitemid 23069938)
10. Brigelius-Flohe R, Traber MG. Vitamin E: function and metabolism. FASEB J 1999;13:1145-55. (Pubitemid 29300361)
11. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol 1994;4:1-10.
12. Albanes D, Malila N, Taylor PR, Huttunen JK, Virtamo J, Edwards BK, et al. Effects of supplemental alpha-tocopherol and beta-carotene on colorectal cancer: results from a controlled trial (Finland). Cancer Causes Control 2000;11:197-205. (Pubitemid 30182136)
13. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440-6. (Pubitemid 28160635)
14. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:56-65. (Pubitemid 41002839)
15. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51.
16. Hensley K, Benaksas EJ, Bolli R, Comp P, Grammas P, Hamdheydari L, et al. New perspectives on vitamin E: gamma-tocopherol and carboxyelthylhydroxychroman metabolites in biology and medicine. Free Radic Biol Med 2004;36:1-15. (Pubitemid 38068287)
17. Kline K, Lawson KA, Yu W, Sanders BG. Vitamin E and breast cancer prevention: current status and future potential. J Mammary Gland Biol Neoplasia 2003;8:91-102. (Pubitemid 38129952)
18. Bairati I, Meyer F, Gelinas M, Fortin A, Nabid A, Brochet F, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 2005;97:481-8. (Pubitemid 40590429)
19. Lee HJ, Ju J, Paul S, So JY, DeCastro A, Smolarek A, et al. Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-gamma. Clin Cancer Res 2009;15:4242-9.
20. Smolarek AK, So JY, Thomas PE, Lee HJ, Paul S, Dombrowski A, et al. Dietary tocopherols inhibit cell proliferation, regulate expression of ERalpha, PPARgamma, and Nrf2, and decrease serum inflammatory markers during the development of mammary hyperplasia. Mol Carcinog 2012.
21. Zhao Y, Lee MJ, Cheung C, Ju JH, Chen YK, Liu B, et al. Analysis of multiple metabolites of tocopherols and tocotrienols in mice and humans. J Agric Food Chem 2010;58:4844-52.
22. Lee HJ, So JY, DeCastro A, Smolarek A, Paul S, Maehr H, et al. Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. J Steroid Biochem Mol Biol 2010;121:408-12.
23. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63-9. (Pubitemid 38821193)
24. Welsch CW. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res 1985;45:3415-43. (Pubitemid 15226403)
25. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ. Comparative study of human and rat mammary tumorigenesis. Lab Invest 1990;62:244-78. (Pubitemid 20124262)
26. Smolarek AK, Suh N. Chemopreventive activity of vitamin E in breast cancer: a focus on gamma- and delta-tocopherol. Nutrients 2011;3:962-86.
27. Fiaschi T, Chiarugi P. Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison. Int J Cell Biol 2012;2012:762-825.
28. Jiang Q, Christen S, Shigenaga MK, Ames BN. Gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. Am J Clin Nutr 2001;74:714-22. (Pubitemid 33101790)
29. Jiang Q, Ames BN. Gamma-tocopherol, but not alpha-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB J 2003;17:816-22. (Pubitemid 36538656)
30. Jiang Q, Elson-Schwab I, Courtemanche C, Ames BN. Gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci U S A 2000;97:11494-9.
31. Jiang Q, Lykkesfeldt J, Shigenaga MK, Shigeno ET, Christen S, Ames BN. Gamma-tocopherol supplementation inhibits protein nitration and ascorbate oxidation in rats with inflammation. Free Radic Biol Med 2002;33:1534-42. (Pubitemid 35351597)
32. Christen S, Woodall AA, Shigenaga MK, Southwell-Keely PT, Duncan MW, Ames BN. Gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol: physiological implications. Proc Natl Acad Sci U S A 1997;94:3217-22.
33. Li GX, Lee MJ, Liu AB, Yang Z, Lin Y, Shih WJ, et al. Delta-tocopherol is more active than alpha - or gamma -tocopherol in inhibiting lung tumorigenesis in vivo. Cancer Prev Res 2011;4:404-13.
34. Khor TO, Yu S, Kong AN. Dietary cancer chemopreventive agents - targeting inflammation and Nrf2 signaling pathway. Planta Med 2008;74:1540-7.
35. Barve A, Khor TO, Nair S, Reuhl K, Suh N, Reddy B, et al. Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int J Cancer 2009;124:1693-9.
36. Chen C, Kong AN. Dietary cancer-chemopreventive compounds: from signaling and gene expression to pharmacological effects. Trends Pharmacol Sci 2005;26:318-26. (Pubitemid 40733525)
37. Bonofiglio D, Gabriele S, Aquila S, Catalano S, Gentile M, Middea E, et al. Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator- activated receptor gamma signaling in breast cancer cells. Clin Cancer Res 2005;11:6139-47. (Pubitemid 41262940)
38. Mansure JJ, Nassim R, Kassouf W. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol Ther 2009;8:6-15.
39. Brigelius-Flohe R, Kelly FJ, Salonen JT, Neuzil J, Zingg JM, Azzi A. The European perspective on vitamin E: current knowledge and future research. Am J Clin Nutr 2002;76:703-16.
40. Kline K, Lawson KA, Yu W, Sanders BG. Vitamin E and cancer. Vitam Horm 2007;76:435-61.